Business Context and Reporting Period
This Form 8-K Current Report was filed by Mink Therapeutics, Inc. (INKT) on March 13, 2026. The filing discloses corporate governance changes regarding the appointment of key financial officers effective as of the report date.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on personnel appointments.
Material Changes
The primary material change reported is the appointment of two new officers to the Company's financial leadership team, effective March 13, 2026:
- Principal Financial Officer: Melissa Orilall, currently Vice President, Global Financial Operations at Agenus Inc.
- Principal Accounting Officer: Austin Charette, currently Senior Director, Financial Reporting and Compliance at Agenus Inc.
Both officers provide services to Mink Therapeutics through an Amended and Restated Intercompany Services Agreement with Agenus Inc. Neither officer receives direct compensation from Mink Therapeutics for these services.
Guidance, Outlook, and Risks
The filing contains no financial guidance, forward-looking outlook, or discussion of specific risks or contingencies related to the Company's operations or financial condition. The appointments were not made pursuant to any new compensatory arrangements or understandings beyond the existing intercompany agreement.
Investor Verification Checklist
- Verify the terms and duration of the Amended and Restated Intercompany Services Agreement between Mink Therapeutics and Agenus Inc.
- Confirm the extent of Agenus Inc.'s operational and financial control over Mink Therapeutics given the shared leadership structure.
- Review Agenus Inc.'s recent financial filings to assess the stability of the entity providing the financial leadership services.
- Check for any subsequent filings regarding the departure of previous financial officers.